Canadian patients with cystic fibrosis (CF) will have to wait for access to Orkambi (lumacaftor/ivacaftor), whose submission will be reconsidered at…
Articles by Inês Martins, PhD
Suppressing a specific type of immune cell called Th17 may aid cystic fibrosis (CF) patients with Pseudomonas aeruginosa infection, one of the…
Interleukin-22 is known to protect against respiratory pathogens through its ability to mediate mucosal immunity and tissue regeneration. But new research into its…
Researchers are working on a way to deliver high doses of a common anti-inflammatory — ibuprofen — directly into the lungs…
To date, 2,007 mutations have been identified in the CFTR gene, but their contribution for cystic fibrosis (CF) development has…
Vertex Pharmaceuticals recently revealed new clinical data on real-world long-term outcomes in cystic fibrosis (CF) patients treated with Kalydeco (ivacaftor). The company…
Raptor Pharmaceutical recently announced new clinical data from a Phase 3 trial evaluating the efficacy of Quinsair (levofloxacin) versus tobramycin…
Healthcare workers with cystic fibrosis (CF) are more likely to contract methicillin-resistant staphylococcus aureus (MRSA) infections than CF patients not in healthcare scenarios, according…
Researchers partially restored the function of the CFTR protein in lung cells isolated from cystic fibrosis (CF) patients by blocking a…
Nivalis Therapeutics announced the dosing of a first patient in a Phase 2 clinical trial evaluating the efficacy and safety of its investigational…